In The News:
Dale Gerding, M.D., a professor of medicine at Loyola University’s Stritch School of Medicine in Chicago says, “Antibiotics disrupt your normal microbiota and when they do that they enable you to be susceptible to C. diff.”
Even after treatment, C. diff comes back in 20 percent of patients.
O’Riordan had it six times in less than a year.
Dr. Gerding has patented a novel treatment to prevent recurrence by giving patients a non-toxic strain of C. diff.
“Instead of replacing the microbiota, which is what a fecal transplant does, all this does is replace the C. Diff,” explains Dr. Gerding
Stuart Johnson, M.D., an infectious disease physician and professor of medicine at Loyola University’s Stritch School of Medicine says, “You can think of it as a probiotic, we like to think of it as a bio-therapeutic.”
They believe a non-toxic strain of C. diff could be the answer to protecting hundreds of thousands of people against the fastest growing superbug.
“I don’t want to go through this again, ever. Ever! Anything even remotely like that,” says O’Riordan.
Dr. Gerding said the non-toxic strain of C. diff doesn’t have any serious side effects, and it stays in the body for up to five months, which is why it cut the recurrence rate to two percent in studies.
Dr. Gerding is currently looking for a company to develop the treatment. It would be given in pill or liquid form.
For article in its entirety please click on the link below: